Health status measurement in Parkinson's disease: Validity of the PDQ-39 and Nottingham Health Profile

Movement Disorders

Volumn 18, Issue 7, 2003, Pages 773-783

  Hagell, Peter ^a   Whalley, Diane ^b   McKenna, Stephen P ^b   Lindvall, Olle ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b GALEN RESEARCH   (United Kingdom)

Author keywords

Evaluation; Health status; Measurement; Parkinson's disease; Psychometrics; Rasch analysis

Indexed keywords

AGE; CONTROLLED STUDY; DISEASE SEVERITY; FEASIBILITY STUDY; GENDER; HEALTH STATUS; HEALTH SURVEY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PARKINSON DISEASE; POSTAL MAIL; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; RELIABILITY; REVIEW; SCORING SYSTEM; UNITED KINGDOM; VALIDATION PROCESS;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; CROSS-CULTURAL COMPARISON; CROSS-SECTIONAL STUDIES; FEASIBILITY STUDIES; FEMALE; GERIATRIC ASSESSMENT; HEALTH STATUS; HEALTH SURVEYS; HUMANS; LANGUAGE; MALE; MATHEMATICAL COMPUTING; MIDDLE AGED; PARKINSON DISEASE; PSYCHOMETRICS; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; SICKNESS IMPACT PROFILE;

EID: 0042591649     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10438     Document Type: Review

References (65)

1. Dunnett SB, Bjorklund A. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 1999; 399(Suppl.):A32-A39.
2. Brod M, Mendelson GA, Roberts B. Patients' experience of Parkinson's disease. J Gerontol B Psychol 1998;53:P213-P222.
3. Vingerhoets FJG, Schulzer M, Calne DB, et al. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neural 1997;41:58-64.
4. Mitchell SL, Harper DW, Lau A, et al. Pattern of outcome measurement in Parkinson's disease clinical trials. Neuroepidemiology 2000;19:100-108.
5. Devinsky O. Outcome research in neurology: incorporating health-related quality of life. Ann Neurol 1995;37:141-142.
6. Hobart JC, Freeman JA, Lamping DL. Physician and patient-oriented outcomes in progressive neurological disease: which to measure? Curr Opin Neurol 1996;9:441-444.
7. Defer GL, Widner H, Marie RM, et al. Core Assessment Program for Surgical Interventional Therapies in Parkinson's Disease (CAPSIT-PD). Mov Disord 1999;14:572-584.
8. Morrish P. Is it time to abandon functional imaging in the study of neuroprotection?. Mov Disord 2002;17:229-232.
9. World Health Organization. The first ten years of the WHO. Geneva: World Health Organization; 1958.
10. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989; 27(Suppl.):S217-S232.
11. Fayers PM, Machin D. Quality of life: assessment, analysis and interpretation. West Sussex: John Wiley and Sons; 2000.
12. Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well-being for individuals with Parkinson' disease. Qual Life Res 1995;4:241-248.
13. Jenkinson C, Fitzpatrick R, Peto V. The Parkinson's disease questionnaire. User manual for the PDQ-39, PDQ-8 and PDQ Summary Index. Oxford: Health Services Research Unit, Department of Public Health, University of Oxford; 1998.
14. Marinus J, Ramaker C, van Hilten JJ, Stiggelbout AM. Health related quality of life in Parkinson's disease: a systematic review of disease specific instruments. J Neurol Neurosurg Psychiatry 2002; 72:241-248.
15. Hunt SM, McKenna SP, McEwen J, Backett EM, Williams J, Papp E. A quantitative approach to perceived health status: a validation study. J Epidemiol Community Health 1980;34:281-286.
16. European Group for Quality of Life Assessment and Health Measurement. European guide to the Nottingham Health Profile. Brookwood, Surrey: Brookwood Medical Publications; 1993.
17. Peto V, Jenkinson C. Quality of life measures in Parkinson's disease. In: Marinez-Martin P, Koller WC, editors. Quality of life in Parkinson's disease. Barcelona: MASSON, SA; 1999. p 37-53.
18. Wiklund I, Romanus B, Hunt S. Self-assessed disability in patients with arthrosis of the hip joint: reliability of the Swedish version of the Nottingham Health Profile. Int Disabil Stud 1988;10:159-163.
19. Streiner DL, Norman GR. Health measurement scales: a practical guide to their development and use. 2nd ed. Oxford: Oxford University Press; 1995.
20. Hobart JC, Lamping DL, Thompson AJ. Evaluating neurological outcome measures: the bare essentials. J Neurol Neurosurg Psychiatry 1996;60:127-130.
21. McDowell I, Newell C. Measuring health: a guide to rating scales and questionnaires. 2nd ed. Oxford: Oxford University Press; 1996.
22. Cella DF, Lloyd SR, Wright BD. Cross-cultural instrument equating: current research and future directions. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials, 2nd ed. Philadelphia: Lippincott-Raven Publishers; 1996. p 707-715.
23. Leplege A, Ecosse E, and WHOQOL Rasch Project Scientific Committee. Methodological issues in using the Rasch model to select cross culturally equivalent items in order to develop a quality of life index: the analysis of four WHOQOL-100 data sets (Argentina, France, Hong Kong, United Kingdom). J Appl Meas 2000;1:372-392.
24. McKenna SP, Hunt SM, Tennant A. The development of a patient-completed index of distress from the Nottingham Health Profile: a new measure for use in cost-utility studies. Br J Med Econ 1993; 6:13-24.
25. Whalley D. Recent advances in the evaluation of the scaling properties of health status and quality of life instruments. J D'Econ Med 1996;14:73.
26. Martinez-Martin P, Grandas F, Linazasoro G, et al. Conversion to controlled-release levodopa/carbidopa treatment and quality of life as measured by the Nottingham Health Profile. Neurologia 1999; 14:28-35.
27. McKenna SP. The Nottingham Health Profile/Distress: users guide. Manchester: Galen Research; 1993.
28. Hagell P, Sandlund B. Patients' self-assessment of disease and symptom severity in Parkinson's disease. Qual Life Res 2000;9: 285.
29. Gill TM, Feinstein AR. A critical appraisal of the quality of quality of life measurements. JAMA 1994;272:619-625.
30. Koplas PA, Gans HB, Wisely MP, et al. Quality of life and Parkinson's disease. J Gerontol Med Sci 1999;54A:M197-M202.
31. Simmons Z, Bremer BA, Robbins RA, et al. Quality of life in ALS depends on factors other than strength and physical function. Neurology 2000;55:388-392.
32. Holmes WC, Shea JA. Performance of a new, HIV/AIDS-targeted quality of life (HAT-QoL) instrument in asymptomatic seropositive individuals. Qual Life Res 1997;6:561-571.
33. McHorney CA, Ware JE, Lu JFR, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994;32:40-66.
34. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951;16:297-334.
35. Cortina JM. What is coefficient alpha? An examination of theory and applications. J Appl Psychol 1993;78:98-104.
36. Clark AL, Watson D. Constructing validity: basic issues in objective scale development. In: Kazdin AE, editor. Methodological issues and strategies in clinical research. 2nd ed. Washington: American Psychological Association; 1998. p 215-239.
37. Nunnally JC, Bernstein IH. Psychometric theory. 3rd ed. New York: McGraw-Hill; 1994.
38. Schrag A, Jahanshahi M, Quinn N. How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 2000;15:1112-1118.
39. Rasch G. Probabilistic models for some intelligence and attainment tests. Chicago: University of Chicago Press; 1980.
40. Wright BJ, Stone MH. Best test design. Chicago: MESA Press; 1979.
41. Wright BJ, Masters GN. Rating scale analysis. Chicago: MESA Press; 1982.
42. Bond TG, Fox CM. Applying the Rasch model: fundamental measurement for the human sciences. Mahwah, NJ: Lawrence Erlbaum Associates, Inc; 2001.
43. Scheuneman JD, Subhiyah RG. Evidence for the validity of a Rasch model technique for identifying differential item functioning. J Outcome Meas 1998;2:33-42.
44. Smith RM, Schumacker RE, Bush MJ. Using item mean squares to evaluate fit to the Rasch model. J Outcome Meas 1998;2:66-78.
45. Smith RM. Fit analysis in latent trait measurement models. J Appl Meas 2000;1:199-218.
46. Smith EV Jr. Evidence for the reliability of measures and validity of measure interpretation: a Rasch measurement perspective. J Appl Meas 2001;2:281-311.
47. Tesio L, Cantagallo A. The Functional Assessment Measure (FAM) in closed traumatic brain injury patients: a Rasch-based psychometric study. J Outcome Meas 1998;2:79-96.
48. Linacre JM. Sample size and item calibration stability. Rasch Measure Trans 1994;7:328.
49. Hobart JC, Cano SJ, Thompson AJ. What sample sizes for reliability and validity. Qual Life Res 2002;11:636.
50. Bushnell DM, Martin ML. Quality of life and Parkinson's disease: translation and validation of the US Parkinson's Disease Questionnaire (PDQ-39). Qual Life Res 1999;8:345-350.
51. Martinez-Martin P, Frades Payo B and The Grupo Centro for Study of Movement Disorders. Quality of life in Parkinson's disease: validation study of the PDQ-39 Spanish version. J Neurol 1998;245(Suppl. 1):S34-S38.
52. Martinez-Martin P, Frades B, Jimenez Jimenez FJ, Pondal M, Lopez Lozano JJ, Vela L, Vazquez A, del Val Fernandez J, Divi M, Fabregat N, Tuldra A, Crespo Maraver MC, Molinero LM. The PDQ-39 Spanish version: reliability and correlation with the short-form health survey (SF-36). Neurologia 1999;14:159-163.
53. Katsarou Z, Bostantjopoulou S, Peto V, Alevriadou A, Kiosseoglou G. Quality of life in Parkinson's disease: Greek translation and validation of the Parkinson's disease questionnaire (PDQ-39). Qual Life Res 2001;10:159-163.
54. Damiano AM, McGrath MM, Willian MK, Snyder CF, LeWitt PA, Reyes PF, Richter RR, Means ED. Evaluation of a measurement strategy for Parkinson's disease: assessing patient health-related quality of life. Qual Life Res 2000;9:87-100.
55. Hunt S. The problem of quality of life. Qual Life Res 1997;6:205-212.
56. McKenna SP, Whalley D, Doward LC. Which outcomes are important in schizophrenia. Int J Methods Psychiatr Res 2000; 9(Suppl. 1):S58-S67.
57. Michalos AC, Zumbo BD, Hubley A. Health and the quality of life. Soc Indic Res 2000;51:245-286.
58. Smith KW, Avis NE, Assmann SF. Distinguishing between health status and quality of life in quality of life research: a meta-analysis. Qual Life Res 1999;8:447-459.
59. Engstrom B, Nordeson A. What neurological patients regard as quality of life. J Clin Nuts 1995;4:177-183.
60. Andrich D. Category ordering and their utility. Rasch Measure Trans 1996;9:464-465.
61. Linacre JM. Category disordering vs step disordering. Rasch Measure Trans 1999;13:675-678.
62. Tsang KL, Chi I, Ho SL, Lou VW, Lee TMC, Chu LW. Translation and validation of the standard Chinese version of PDQ-39: a quality-of-life measure for patients with Parkinson's disease. Mov Disord 2002;17:1036-1040.
63. Silverstein B, Fischer WP, Kilgore KM, Harley P, Harvey RF. Applying psychometric criteria to functional assessment in medical rehabilitation: II. Defining interval measures. Arch Phys Med Rehabil 1992;73:507-518.
64. Koller WC, Hutton JT, Tolosa E, et al. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Neurology 1999;53:1012-1019.
65. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56(Suppl. 5):S1-S88.